Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

4.875 +0.205 (+4.39%)

Streaming Delayed Price Updated: 12:38 PM EDT, Sep 28, 2026 Add to My Watchlist

Price and Volume

Volume	1,546,067
Open	4.640
Bid (Size)	4.870 (1,500)
Ask (Size)	4.880 (1,000)
Prev. Close	4.670
Today's Range	4.560 - 4.890
52wk Range	3.100 - 7.300
Shares Outstanding	64,465,037
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

These 3 Risky Stocks Could Be Sitting on 100% Upside ↗

September 07, 2026

Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks.

Via MarketBeat

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 04, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Performance

YTD	-7.1%	-7.1%
1 Month	-15.5%	-15.5%
3 Month	-27.6%	-27.6%
6 Month	+19.8%	+19.8%
1 Year	+54.3%	+54.3%

More News

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call ↗

August 18, 2026

Via The Motley Fool

Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗

May 06, 2026

Via Chartmill

Taysha Gene Therapies Inc (NASDAQ:TSHA) Reports Q4 2025 Revenue Beat and Key Rett Syndrome Program Updates ↗

March 19, 2026

Via Chartmill

Taysha Gene Therapies Q2 Earnings Call Highlights ↗

August 11, 2026

Via MarketBeat

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 07, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 04, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

August 03, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗

July 12, 2026

Via The Motley Fool

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

June 25, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

June 24, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 24, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

June 22, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha (TSHA) Q1 2026 Earnings Transcript ↗

May 07, 2026

Via The Motley Fool

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 06, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

April 29, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

April 27, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

Via MarketMinute

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Via The Motley Fool

Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗

March 19, 2026

Via The Motley Fool

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

March 19, 2026

From Taysha Gene Therapies, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Taysha Gene Therapies, Inc. - Common Stock publicly traded?

Yes, Taysha Gene Therapies, Inc. - Common Stock is publicly traded.

What exchange does Taysha Gene Therapies, Inc. - Common Stock trade on?

Taysha Gene Therapies, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Taysha Gene Therapies, Inc. - Common Stock?

The ticker symbol for Taysha Gene Therapies, Inc. - Common Stock is TSHA on the Nasdaq Stock Market

What is the current price of Taysha Gene Therapies, Inc. - Common Stock?

The current price of Taysha Gene Therapies, Inc. - Common Stock is 4.875

When was Taysha Gene Therapies, Inc. - Common Stock last traded?

The last trade of Taysha Gene Therapies, Inc. - Common Stock was at 09/28/26 12:38 PM ET

What is the market capitalization of Taysha Gene Therapies, Inc. - Common Stock?

The market capitalization of Taysha Gene Therapies, Inc. - Common Stock is 314.27M

How many shares of Taysha Gene Therapies, Inc. - Common Stock are outstanding?

Taysha Gene Therapies, Inc. - Common Stock has 314M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.